摘要:
The invention pertains to compound of Formula (I) wherein X, Y, Z, R1, R2, R3, R4, A, and A′ are described herein. Formula (I) compounds can be used in pharmaceutical compositions, useful for the treatment of disease, in particular cardiovascular conditions and more particularly cardiomyopathies, as well as other related conditions.
摘要:
The present invention relates to a polymerizable composition comprising at least one ethylenically unsaturated, polymerizable compound and at least one oxime sulfonate compound of the formula (I) QAaBbCc where a is 0, 1, 2, 3, 4 or 6, b is 0, 1, 2, 3, 4 or 6, and c is 0, 1, 2, 3, 4 or 6, where the sum of a+b+c is 1, 2, 3, 4 or 6 where (A) is a group (B) is a group (C) is a group where # denotes the point of attachment to Q; X is S or NR14 and Q, R1, R2, R3 and R14 are as defined in claim 1 and in the description. The present invention also relates to the use of the this composition, to novel oxime sulfonates and the use of the oxime sulfonates as thermal curing promoter.
摘要翻译:本发明涉及包含至少一种烯属不饱和的可聚合化合物和至少一种式(I)QAaBbCc的肟磺酸酯化合物的可聚合组合物,其中a为0,1,2,3,4或6,b为0, 1,2,3,4或6,c为0,1,2,3,4或6,其中a + b + c的和为1,2,3,4或6,其中(A)为 组(B)是组(C)是其中#表示与Q的连接点的组; X是S或NR14,Q,R1,R2,R3和R14如权利要求1和说明书中所定义。 本发明还涉及该组合物用于制备新型肟磺酸盐和使用肟磺酸盐作为热固化促进剂的用途。
摘要:
The present application describes general process for the preparation of amino-substituted gamma-lactams involving the reaction of synthons of the general Formulae (I) and (VI): with amines. The processes are amenable to solid phase synthetic techniques and therefore allow the efficient incorporation of amino-substituted gamma-lactams into a wide variety of structural scaffolds, including, in particular peptides.
摘要:
The present invention provides a compound represented by the formula (I): wherein R1 represents a hydrogen atom, a halogen atom or a C1-C6 alkyl group which may have one or more halogen atoms, A1 represents a divalent connecting group, X1 represents a C2-C36 heterocyclic group and one or more —CH2— in the C2-C36 heterocyclic group can be replaced by —CO— or —O—, R2 is independently in each occurrence a halogen atom, a hydroxyl group, a C1-C24 hydrocarbon group, a C1-C12 alkoxy group, a C2-C4 acyl group or a C2-C4 acyloxy group, and m represents an integer of 0 to 10.
摘要:
A process is disclosed for synthesizing large quantities of a compound of formula I ##STR1## wherein a solution of a compound of formula II ##STR2## is mixed with a solution of a compound of formula III ##STR3## under suitable process conditions, and wherein A, same or different, is N--R, O, S, CRR' or P(O)R, and R and R' are hydrogen, alkyl, alkylidene, aryl, tosyl, allyl or benzyl, and B is O.Compounds of formula I may be reduced to form an azacorand of formula IV ##STR4## wherein K and L, same or different, are N--R, O, S, CRR', or P(O)R, and R and R' are hydrogen, alkyl, alkylidene, aryl, tosyl, allyl or benzyl.Also disclosed in a compound of formula IV synthesized in accordance with the above procedure wherein K and L are not both O or S.
摘要:
The oxidative functionalization of olefins is a common method for the formation of vicinal carbon-heteroatom bonds. However, oxidative methods to transform allenes into synthetic motifs containing three contiguous carbon-heteroatom bonds are much less developed. The use of bicyclic methylene aziridines (MAs), prepared via intramolecular allene aziridination, as scaffolds for functionalization of all three allene carbons, among other reactions, is described herein.
摘要:
The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia.
摘要:
Compounds of the formula: ##STR1## are disclosed. These compounds inhibit the angiotensinogen-cleaving action of the natural proteolytic enzyme, renin, and are useful in treating, preventing or managing renin-associated hypertension, hyperaldosteronism, congestive heart failure, and glaucoma.
摘要:
A composition comprising a chelating compound which is a macrocyclic compound containing at least two coordinating centers in the ring, at least one of which is a neutral base moiety, and an organic acid containing at least one alkyl or alkenyl group containing 8 or more carbon atoms. The macrocyclic compound contains at least 10 ring atoms and especially at least 12 ring atoms. The neutral base moiety is typically a nitrogen moiety. Preferably there are at least four coordinating centers at least two of which are neutral base moities. The acid can be an alkyl or alkenyl substituted acid for example a long chain carboxylic acid. The composition can be used as an extractant system for the selective extraction of metals from an aqueous phase into an organic phase.